Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: A comparative overview and future horizons

Expert Opinion on Drug Delivery

Volumn 13, Issue 3, 2016, Pages 389-400

  Thabit, Hood ^a,b   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Continuous subcutaneous insulin infusion; insulin pump; multiple daily injections; type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

CLINICAL PRACTICE; DRUG ABSORPTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; QUALITY OF LIFE;

ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; QUALITY OF LIFE;

EID: 84959539485     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1115013     Document Type: Review

References (72)

1. Nathan DM, Cleary PA, Backlund JY., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353 (25): 2643-2653.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329 (14): 977-986.
3. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007; 77 (1): 1-15.
4. Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H., et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014; 2 (7): 553-561.
5. Fullerton B, Jeitler K, Seitz M., et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014; 2: CD009122.
6. Barnett AH, Owens DR. Insulin analogues. Lancet. 1997; 349 (9044): 47-51.
7. Lauritzen T, Faber OK, Binder C. Variation in 125I-insulin absorption and blood glucose concentration. Diabetologia. 1979; 17 (5): 291-295.
8. Owens DR, Coates PA, Luzio SD., et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000; 23 (6): 813-819.
9. Lepore M, Pampanelli S, Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49 (12): 2142-2148.
10. Soran H, Younis N. Insulin detemir: a new basal insulin analogue. Diabetes Obes Metab. 2006; 8 (1): 26-30.
11. Heise T, Hermanski L, Nosek L., et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14 (9): 859-864.
12. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012; 14 (9): 780-788.
13. Luijf YM, van Bon AC, Hoekstra JB., et al. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010; 33 (10): 2152-2155.
14. Pickup JC, Keen H, Parsons JA., et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978; 1 (6107): 204-207.
15. Tamborlane WV, Sherwin RS, Genel M., et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. 1979; 300 (11): 573-578.
16. Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol. 2011; 5 (1): 129-135.
17. White HD, Goenka N, Furlong NJ., et al. The U.K. service level audit of insulin pump therapy in adults. Diabet Med. 2014; 31 (4): 412-418.
18. Selam S. CSII in Europe: where are we, where are we going? An analysis of articles published in Infusystems International. Diabetes Res Clin Pract. 2006; 74 (Suppl. 2): S123-S126.
19. Pozzilli P, Battelino T, Danne T., et al. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2015. DOI: 10.1002/dmrr.2653.
20. Grunberger G, Bailey TS, Cohen AJ., et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010; 16 (5): 746-762.
21. Maahs DM, Hermann JM, DuBose SN., et al. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia. 2014; 57 (8): 1578-1585.
22. Johnson SR, Cooper MN, Jones TW., et al. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia. 2013; 56 (11): 2392-2400.
23. Weintrob N, Benzaquen H, Galatzer A., et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics. 2003; 112 (3 Pt 1): 559-564.
24. Misso ML, Egberts KJ, Page M., et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010; 1: CD005103.
25. Starkman H, Frydman E, Bustami R. Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control. J Pediatr Endocrinol Metab. 2011; 24 (5-6): 369-371.
26. DeVries JH, Snoek FJ, Kostense PJ., et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002; 25 (11): 2074-2080.
27. Hoogma RP, Hammond PJ, Gomis R., et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med. 2006; 23 (2): 141-147.
28. Skogsberg L, Fors H, Hanas R., et al. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008; 9 (5): 472-479.
29. Bolli GB, Kerr D, Thomas R., et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care. 2009; 32 (7): 1170-1176.
30. Doyle EA, Weinzimer SA, Steffen AT., et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004; 27 (7): 1554-1558.
31. Bergenstal RM, Tamborlane WV, Ahmann A., et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363 (4): 311-320.
32. Ly TT, Maahs DM, Rewers A., et al. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2014; 15 (Suppl. 20): 180-192.
33. Katz ML, Volkening LK, Anderson BJ., et al. Contemporary rates of severe hypoglycaemia in youth with type 1 diabetes: variability by insulin regimen. Diabet Med. 2012; 29 (7): 926-932.
34. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008; 25 (7): 765-774.
35. Pedersen-Bjergaard U, Pramming S, Heller SR., et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004; 20 (6): 479-486.
36. Müller-Godeffroy E, Treichel S, Wagner VM., et al. Investigation of quality of life and family burden issues during insulin pump therapy in children with type 1 diabetes mellitus-a large-scale multicentre pilot study. Diabet Med. 2009; 26 (5): 493-501.
37. Knight S, Northam E, Donath S., et al. Improvements in cognition, mood and behaviour following commencement of continuous subcutaneous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study. Diabetologia. 2009; 52 (2): 193-198.
38. Nuboer R, Borsboom GJ, Zoethout JA., et al. Effects of insulin pump vs. injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomized, prospective comparison. Pediatr Diabetes. 2008; 9 (4 Pt 1): 291-296.
39. Wilson DM, Buckingham BA, Kunselman EL., et al. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005; 28 (1): 15-19.
40. Fox LA, Buckloh LM, Smith SD., et al. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care. 2005; 28 (6): 1277-1281.
41. Yeh HC, Brown TT, Maruthur N., et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012; 157 (5): 336-347.
42. Clements M, Matuleviciene V, Attvall S., et al. Predicting the effectiveness of insulin pump therapy on glycemic control in clinical practice: a retrospective study of patients with type 1 diabetes from 10 outpatient diabetes clinics in Sweden over 5 years. Diabetes Technol Ther. 2015; 17 (1): 21-28.
43. Nicolucci A, Maione A, Franciosi M., et al. Quality of life and treatment satisfaction in adults with type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med. 2008; 25 (2): 213-220.
44. Linkeschova R, Raoul M, Bott U., et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med. 2002; 19 (9): 746-751.
45. Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol. 2012; 8 (7): 425-433.
46. Oliver NS, Toumazou C, Cass AE., et al. Glucose sensors: a review of current and emerging technology. Diabet Med. 2009; 26 (3): 197-210.
47. Little SA, Leelarathna L, Walkinshaw E., et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care. 2014; 37 (8): 2114-2122.
48. Bergenstal RM, Tamborlane WV, Ahmann A., et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011; 34 (11): 2403-2405.
49. Hermanides J, Nørgaard K, Bruttomesso D., et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled type 1 diabetes; a randomized controlled trial. Diabet Med. 2011; 28 (10): 1158-1167.
50. Schmidt S, Nørgaard K. Sensor-augmented pump therapy at 36 months. Diabetes Technol Ther. 2012; 14 (12): 1174-1177.
51. Choudhary P, Shin J, Wang Y., et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care. 2011; 34 (9): 2023-2025.
52. Ly TT, Nicholas JA, Retterath A., et al. Analysis of glucose responses to automated insulin suspension with sensor-augmented pump therapy. Diabetes Care. 2012; 35 (7): 1462-1465.
53. Bergenstal RM, Klonoff DC, Garg SK., et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013; 369 (3): 224-232.
54. Buckingham BA, Cameron F, Calhoun P., et al. Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther. 2013; 15 (8): 622-627.
55. Maahs DM, Calhoun P, Buckingham BA., et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014; 37 (7): 1885-1891.
56. Pickup JC, Yemane N, Brackenridge A., et al. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther. 2014; 16 (3): 145-149.
57. Heinemann L, Fleming GA, Petrie JR., et al. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia. 2015; 58 (5): 862-870.
58. Heinemann L, Hirsch L, Hovorka R. Lipohypertrophy and the artificial pancreas: is this an issue? J Diabetes Sci Technol. 2014; 8,5,915-917.
59. McVey E, Hirsch L, Sutter DE., et al. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. J Diabetes Sci Technol. 2012; 6 (4): 743-754.
60. Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Sci Technol. 2012; 6 (4): 764-772.
61. Cummins E, Royle P, Snaith A., et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess. 2010; 14 (11): iii-iv, xi-xvi, 1-181.
62. Steineck I, Cederholm J, Eliasson B., et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. BMJ. 2015; 350: h3234.
63. Anderson BJ, Brackett J, Ho J., et al. An office-based intervention to maintain parent-adolescent teamwork in diabetes management. Impact on parent involvement, family conflict, and subsequent glycemic control. Diabetes Care. 1999; 22 (5): 713-721.
64. Murphy HR, Wadham C, Rayman G., et al. Integrating pediatric diabetes education into routine clinical care: the Families, Adolescents and Childrens Teamwork Study (FACTS). Diabetes Care. 2006; 29 (5): 1177.
65. Sawtell M, Jamieson L, Wiggins M., et al. Implementing a structured education program for children with diabetes: lessons learnt from an integrated process evaluation. BMJ Open Diabetes Res Care. 2015; 3 (1): e000065.
66. Hopkins D, Lawrence I, Mansell P., et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care. 2012; 35 (8): 1638-1642.
67. Gunn D, Mansell P. Glycaemic control and weight 7 years after Dose Adjustment For Normal Eating (DAFNE) structured education in type 1 diabetes. Diabet Med. 2012; 29 (6): 807-812.
68. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011; 7 (7): 385-395.
69. Phillip M, Battelino T, Atlas E., et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013; 368 (9): 824-833.
70. Hovorka R, Allen JM, Elleri D., et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010; 375 (9716): 743-751.
71. Thabit H, Lubina-Solomon A, Stadler M., et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2014; 2 (9): 701-709.
72. Thabit H, Tauschmann M, Allen JM., et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015. DOI: 10.1056/NEJMoa1509351.